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Objective: Elevated levels of C-reactive protein (CRP) and D-dimer (DD) have been associated with the presence and
progression of various forms of atherosclerotic disease, particularly coronary heart disease. We hypothesize that there is
a relationship between elevated levels of baseline CRP and DD and progression of peripheral arterial disease (PAD) in
patients with symptomatic PAD. The current study is a prospective evaluation of this hypothesis.
Methods: Between 1996 and 2003, 384 subjects were enrolled in a National Institutes of Health-sponsored blinded,
prospective trial evaluating the effects of multiple atherosclerotic risk factors on progression of symptomatic PAD. Baseline
levels of CRP and D-dimer were obtained in 332 subjects. Subjects were followed every 6 months with clinical history and
exam, ankle-brachial pressure index (ABI), and carotid artery duplex scanning (CDS). The primary study end point was a
composite of ABI progression, CDS progression, stroke, myocardial infarction, amputation, and death from cardiovascular
disease. Secondary end points included each of the components of the primary end point. The relationship between time to the
various endpoints and baseline CRP andDD levels was examined by life-table analysis and Cox proportional hazards analysis.
Results: Adequate baseline samples for CRP and DD were available in 332 subjects (mean age, 67 years; 57.8% men) with
mean follow-up of 38.4 months (range, 1 to 99 months). Mean baseline levels ( SD) for CRP were 0.8  1.14 (range,
0.03 to 13.0), and mean DD levels were 227.4  303.3 (range, 1.9 to 2744.8). Progression, as defined by the primary
end point, occurred in 48.5% of subjects. Subjects with elevated CRP (highest tertile) were no more likely to have any of
the progression end points than those with the lowest values (lowest tertile) (PNS, log-rank test, for all comparisons).
By univariate analysis, subjects with elevated DD (highest tertile) were significantly more likely to die from any cause
compared with subjects with the lowest DD values (lowest tertile) (P .03, log-rank test). They were, however, no more
likely to reach any of the other progression end points, including the primary end point (P  NS, log-rank test for all
other comparisons). Multivariate analysis showed that DD level was a significant independent variable associated with
occurrence of myocardial infarction (hazard ratio, 2.3; P  .02).
Conclusions: In subjects with symptomatic PAD, elevated baseline DD, a marker of thrombotic activity, was significantly
associated with the occurrence of myocardial infarction. This study did not confirm a relationship between progression
of PAD and baseline DD or CRP during the first 3 years. Baseline DD and CRP do not provide useful risk stratification
in patients at high risk for progression of symptomatic PAD. Future studies should evaluate serial levels of these markers
to assess their utility in predicting progression of symptomatic PAD. (J Vasc Surg 2006;43:772-80.)Atherosclerosis is the leading cause of death and dis-
ability in developed countries. Despite considerable re-
search effort, the cause of this important disease process
remains unknown. Current efforts are focused on identify-
ing risk factors that predispose patients to atherosclerosis.
Well-known risk factors that have been found to increase
the risk of developing symptomatic atherosclerosis include
diabetes mellitus, smoking, hypertension, and hypercholes-
terolemia, among others.1
More recent studies have investigated the influence of
alternative risk factors on the development of atheroscle-
rotic arterial disease.2-5 Nutritional factors such as elevated
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772homocysteine levels have been shown to be associated with
the presence of atherosclerotic arterial disease and its pro-
gression.2 Lipid markers such as lipoprotein(a) and apoli-
poprotein A-1 are associated with premature atheroscle-
rotic disease.3 Inflammatory markers such as C-reactive
protein (CRP) and fibrinogen as well as thrombotic mark-
ers such as fibrin D-dimer (DD) and tissue plasminogen
activator are now known to be associated with both isch-
emic heart disease and peripheral vascular disease.4,5
CRP is a plasma protein that is a marker for systemic
inflammation. Single, elevated CRP levels have been asso-
ciated with an increased risk of ischemic heart disease.6 It
has also been shown that when CRP levels are decreased
with statins, the risk for ischemic coronary events is also
decreased.7 A study of the association between CRP and
peripheral vascular disease (PAD) found that increased
levels of serum CRP were an independent predictor of the
development of symptomatic PAD.8 Elevated levels of
serum CRP are related to the development of cerebrovas-
cular disease.9 CRP levels can be lowered by removal of
atherosclerotic plaque by carotid endarterectomy.10
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 4 Musicant et al 773Fibrin DD is a marker of cross-linked fibrin turnover
and fibrinolysis. Fibrinolysis is a normal part of the inflam-
matory response, and studies suggest that elevated DD
levels may be a measure of the severity of atherosclerosis.5
Elevated levels of DD have been associated with the pres-
ence of both coronary heart disease11 and PAD.12-15 DD
levels have also been found to be inversely associated with
functional performance in patients with and without
PAD.16 Few studies have evaluated the relationship be-
tween these inflammatory and prothrombotic markers and
the progression of atherosclerotic vascular disease. We hy-
pothesize a relationship exists between elevated levels of base-
lineCRP andDDand the progression of PAD in patientswith
PAD. The current study is a prospective evaluation of this
hypothesis.
METHODS
Patient selection. The Homocysteine and Progres-
sion of Atherosclerosis Study (HPAS) is a prospective,
randomized, blinded clinical research study conducted at
Oregon Health & Science University (OHSU) using the
combined facilities of the Division of Vascular Surgery and
the General Clinical Research Center. This study began in
1991 as a long-term follow-up study of patients with symp-
tomatic PADdesigned to examine the relationship between
homocysteine levels, progression of symptomatic PAD, and
vitamin treatment.
HPAS has been divided into two phases. The first phase
was a prospective observational study of the relationship
between homocysteine level, other risk factors, and pro-
gression of symptomatic PAD. The results of the first phase
of HPAS have been reported previously.2
The second phase of HPAS is a prospective, randomized,
double-blinded clinical trial of folate (4mg/day) vs placebo to
prevent progression of symptomatic PAD. The results of this
treatment trial with respect to the influence of the treatment
assignment (folate vs placebo) are being reported separately.
Subjects for the present report were those participating in the
treatment trial, the second phase of HPAS.
Patients were recruited for participation in HPAS if
they had symptomatic PAD in at least one lower extremity,
as indicated by claudication, bypass surgery, rest pain, or
ischemic ulcer with vascular laboratory evidence of PAD
(ankle-brachial index [ABI] 0.90), or symptomatic cere-
bral vascular disease (transient ischemic attack, stroke, ca-
rotid surgery with carotid stenosis 16% diameter reduc-
tion at the symptomatic site), or both. Subjects were not
included unless at least one leg or carotid artery had not
undergone surgery. Patients with unstable disease (limb-
threatening ischemia, repeated transient ischemic attacks)
were not enrolled until they had been treated and attained
a stable status.
HPAS is fully approved by the Institutional Review
Board of OHSU and by the Advisory Committee of the
OHSU General Clinical Research Center. All subjects gave
informed consent for participation.
Baseline clinical data. Before participation in the ran-
domized treatment trial, all subjects provided their medicalhistory and had a physical examination, laboratory testing,
and vascular laboratory testing of the lower extremities and
carotid arteries. Lower-extremity testing included segmen-
tal limb pressures and ankle pressure (ABI) response to
treadmill walking.17 Carotid artery testing was performed
with duplex ultrasound scanning (CDS) using the Univer-
sity of Washington criteria for diagnosis of carotid artery
stenosis: category A, 0% stenosis; category B, 1% to 16%
stenosis; category C, 17% to 49% stenosis; category D, 50%
to 79% stenosis; category D, 80% to 99% stenosis; cate-
gory E, occluded.18
C-reactive protein and D-dimer testing. CRP and
DD levels were determined from blood samples obtained
at baseline. High-sensitivity CRP and DD assays were per-
formed by theOHSUGeneral Clinical ResearchCenter Core
Laboratory. Quality control samples were included in each
assay (2 for CRP, 4 for DD) at concentrations throughout
the assay range. CRP levels were measured by using the
automated Immulite chemiluminescent system (Diagnos-
tic Products Corporation, Los Angels, Calif). The interas-
say coefficient of variation ranged from 6.5% to 7.8%. DD
levels were measured by a modified commercially available
electroimmunoassay kit (Trinity Biotech USA, St. Louis,
Mo). The interassay coefficient of variation ranged from
5.4% to 10.2%.
Follow-up. After baseline data accumulation and ran-
domization, subjects were seen every 6 months. An interval
history and physical examination was performed and vascu-
lar laboratory testing was repeated at each follow-up visit.
Treatment. Subjects underwent standard management
of PAD. Nonoperative management included antiplatelet
therapy with aspirin or clopidogrel, lipid lowering treat-
ment, smoking cessation counseling, and the recommen-
dation for daily walking exercise.
Revascularization for lower-extremity ischemia was
performed for disabling claudication or limb-threatening
ischemia and was performed by the investigators according
to principles published previously.19 Carotid endarterec-
tomy was recommended for asymptomatic progression to
high-grade carotid stenosis or development of hemispheric
symptoms in association with 50% carotid stenosis.20,21
Definition of disease progression. In the HPAS
study, progression of disease includes both lesion-defined
parameters (vascular laboratory) and event-defined param-
eters (clinical events). The primary study end point is a
composite that includes ABI progression, CDS progres-
sion, stroke, myocardial infarction, amputation, and death
from cardiovascular disease. Secondary end points included
each of the components of the primary end point. Nonfatal
progression, as determined by means of symptoms, was
documented during patient interviews at regular 6-month
follow-up visits, by hospital discharge diagnoses, and by
communication with primary care physicians. Death from
any cause was also an end point. Cause of death was
determined from autopsy reports when available or from
hospital discharge summaries or death certificates. Vascular
laboratory progression of lower-extremity disease was de-
fined as a decrease in ABI of 0.15, and CDS progres-
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Data analysis. Data are expressed as means  SD and
ranges.
Univariate analysis: For CRP and DD, subjects with
the highest one third of values were compared with those
with the lowest one third of values, for time to the primary
and each of the secondary end points by life-table methods.
Life tables were compared by log-rank testing.
Multivariate analysis: Hazard ratios (HR) with 95%
confidence intervals (CI) for time to the primary and sec-
ondary end points as dependent variables were calculated
using a Cox proportional hazards model for censored
data. Log-CRP and log-DD were placed into the model
as independent variables, and the model was fully ad-
justed for other independent variables including age, gen-
der, diabetes mellitus, hypertension, log-cholesterol, log-
homocysteine level, and smoking. The variables CRP, DD,
cholesterol, and homocysteine were all highly skewed; the
use of log-transformations reduced the skewness and im-
proved the fit of the models. Because the ranges of values
for log-cholesterol and log-homocysteine were small, we
obtained hazard ratios corresponding to an increase of .10
on the log-scales (ie, an approximate 10% increase on the
original scales). Blinded randomization group for the treat-
ment trial (folate vs placebo) was also entered into the
model as an independent variable.
RESULTS
Subjects. From August 1996 through November
2003, 384 subjects were entered into the study and were
randomized. Of these, 361 subjects returned for at least
one follow-up visit. Adequate baseline samples for CRP and
DDwere available in 332 subjects, and these comprised the
current study group. Mean age was 67.2  9.1 years, and
57.8% of subjects were male. Symptomatic lower-extremity
disease was present at baseline in 270 subjects (82%), and
symptomatic cerebrovascular disease was present in 140
subjects (43%). Eighty-eight subjects (27%) had both
symptomatic lower-extremity disease and cerebrovascular
disease. Mean lowest ABI was 0.75  0.24. Median worst
carotid stenosis was 17% to 49% diameter reduction (UW
class C). Thirty-one percent of subjects were current smok-
ers, and 80% of subjects had been smokers at some point
in time. Additional risk factors for atherosclerosis present at
study entry are listed in Table I.
Follow-up. The mean follow-up period for the 332
subjects in the study group was 38.4  20.4 months
(range, 1 to 99 months).
Nonfatal clinical progression. Nonfatal myocardial
infarction occurred in 13 subjects (3.9%), 11 subjects (3.3%)
had a stroke, and there were t w o amputations (0.6%) (Fig 1).
Vascular laboratory progression. A decrease in ABI
0.15 occurred in 76 subjects (22.9%). An increase in
carotid artery stenosis of one category occurred in 98
subjects (29.5%). Some progression of disease by vascular
laboratory criteria (ABI, CDS, or both) occurred in 142
subjects (42.8%) (Fig 1).Survival. Thirty-eight subjects (11.4%) died during
the follow-up period. Fifty percent of all deaths (19 sub-
jects, 5.7% overall) were attributed to cardiovascular etiol-
ogy (Fig 1).
Primary composite end point. During follow-up,
161 subjects (48.5%) reached the primary composite end
point. When any death was substituted for cardiovascular
death, 175 subjects met the combined end point (52.7%)
(Fig 1).
Baseline plasma C-reactive protein and D-dimer
levels. The mean baseline plasma CRP level for all subjects
was 0.8 1.1 mg/L.Mean baseline DD level for all subjects
was 227.4  303.3 g/mL. Baseline values for these and
other relevant laboratory tests are listed in Table II.
Univariate analysis
By life table, there were no significant differences
between subjects with the highest vs lowest tertiles of
baseline CRP and DD with respect to myocardial infarc-
tion, stroke, amputation, carotid progression, ABI progres-
sion, cardiovascular death, or the primary composite end
point. Death from any cause was significantly more likely to
occur in subjects with elevated baseline DD levels (lowest
Table I. Selected baseline demographics of study
subjects
N  332 (%)
Age (mean  SD) (years) 67.2  9.1
Women 140 (42)
Heart Disease 157 (48)
Hypertension 207 (63)
Current tobacco smoking 101 (31)
Any tobacco use 262 (80)
Diabetes mellitus 69 (21)
Hyperlipidemia 193 (58)
Peripheral arterial disease (PAD) 270 (82.6)
Cerebrovascular disease (CVD) 140 (42.8)
Both PAD and CVD 88 (26.8)
Fig 1. Overall percentage of subjects meeting primary and sec-
ondary end points. ABI, ankle-brachial index; MI, myocardial
infarction.tertile, 6.8% vs highest tertile, 15.5%; P  .03, log-rank
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death from cardiovascular disease, death from any cause,
and occurrence of the primary end point comparing the
highest vs lowest tertiles of subject values for baseline DD
and baseline CRP.
Multivariate analysis
Although randomization group (folate vs placebo) was
not independently associated with the primary or any of the
secondary end points (PNS for all comparisons, data not
shown), we retained randomization group in the multivar-
iate model as it was instrumental in the design of the study
and allowed us to adjust for any undetected effects of
treatment assignment.
No significant differences in end-point occurrence were
associated with age or gender (P  NS for all associations,
data not shown). Age and gender were retained in the
multivariate model because of their known influence on
outcome of atherosclerotic disease from other studies. As
expected, diabetes mellitus, hyperlipidemia, and hyperho-
mocysteinemia were all shown by Cox proportional hazards
analysis to be significantly associated with one or more
aspects of disease progression, as assessed by clinical pro-
gression, vascular laboratory progression, or death (Figs 4
to 7, Table III). These factors were therefore retained in the
multivariate model.
Nonfatal clinical progression. Baseline DD level was
significantly associated with the development of myocar-
dial infarction (HR, 2.3; 95% CI, 1.12 to 4.76; P  .03)
(Fig 4). Diabetes mellitus was also significantly associated
with myocardial infarction (HR, 6.3; 95% CI, 1.59 to
25.28; P  .009) (Table III). No relationship was found
between baseline CRP and myocardial infarction (HR, .63;
95% CI, 0.32 to 1.22; P .17). No significant associations
were found between baseline DD, baseline CRP, and
stroke or amputation, or both (data not shown).
Vascular laboratory progression. There was no sig-
nificant association between baseline CRP and DD and
progression of ABI or CDS, or both (data not shown).
Diabetes mellitus (HR, 1.82; 95% CI, 1.04 to 3.18; P 
.03) and homocysteine (HR, 2.33; 95% CI, 1.17 to 4.61,
P .02) were associated with ABI progression (Table III).
Cholesterol (HR, 3.78; 95% CI, 1.10 to 12.96, P  .03)
was associated with CDS progression (Table III).
Survival. Baseline DD and CRP levels had no signifi-




High-sensitivity C-reactive protein level
(mg/L) 0.8  1.1 (0-1.0)
Fibrin D-dimer level (g/mL) 227  303 (0-130)
Fasting serum cholesterol level (mg/dL) 199  38 (0-199)
Plasma homocysteine level (nmol/mL) 12  6 (4-12)
Plasma creatinine level (mg/dL) 1.3  1.4 (0.7-1.3)cant association with the risk of death from any cause (P .50 for DD; P  .41 for CRP), or with death from cardio-
vascular disease (P  .15 for DD; P  .64 for CRP).
Homocysteine (HR, 4.12; 95% CI, 1.76 to 9.64; P 
.001) and cholesterol (HR, 14.77; 95% CI, 1.70 to 128.2;
P  .01) were associated with death from any cause. Figs 5
and 6 show the hazard ratios associated with cardiovascular
death and death from any cause for the factors included in
the multivariate model.
Primary composite end point. Baseline CRP andDD
had no significant independent association with time to
the primary composite end point (HR, 1.07; 95% CI, 0.91
to 1.25; P .44 for DD; HR, 0.90; 95% CI, 0.75 to 1.08;
P  .26 for CRP) (Fig 7). Homocysteine (HR, 1.65; 95%
CI, 1.00 to 2.73; P  .05) was associated with occurrence
of the primary end point. Fig 7 shows hazard ratios associ-
ated with the various risk factors included in the multivar-
iate model for the primary composite end point.
DISCUSSION
Except for a significant association between baseline
DD and myocardial infarction (P  .04), the hypothesis
tested by this study was not confirmed. Consistent with the
findings of the first phase of the HPAS study,2 elevated
baseline levels of homocysteine were significantly associ-
ated with an increased risk of achieving the composite end
point, which included death from vascular disease, myocar-
dial infarction, ABI decrease, CDS progression, stroke, and
amputation. In the present analysis, a similar association
was not present related to baseline DD or CRP levels.
The association between baseline DD and myocardial
infarction is consistent with previous studies which have
shown that elevated plasma levels of inflammatory and
thrombotic markers, such as CRP and DD, are associated
with the development of ischemic heart disease.6,7,11 Lowe
et al11 were able to show an association between DD and
baseline evidence of heart disease; however, the strength of
this association was reduced in a multivariate analysis.11 Pai
et al6 were able to show a moderate, but significant, inde-
pendent relationship between CRP levels and risk of coro-
nary disease (relative risk, 1.79).
There are several possible explanations for the fact
that our study showed no association between baseline
CRP and progression and minimal association between
DD and progression. First, the sample size may have
been too small to allow for statistical significance. The
widths of the confidence intervals provide information
about the precision of the hazard ratio estimators, and
wide confidence intervals suggest larger sample sizes are
needed. This is suggested by the fact that other well-
established risk factors for progression of atherosclerotic
disease (diabetes mellitus smoking, hypertension, cho-
lesterol, age, gender) were associated with some but by
no means all of the study end points.
Second, the length of follow-up may have been too
short to allow an adequate number of clinical events to
occur. Although one half of the subjects experienced an
end point event, most of the end points occurring in this
study were asymptomatic progression of disease detected
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events, including myocardial infarction, stroke, amputa-
tion, and death was small. Symptomatic progression of
atherosclerotic disease has been associated with CRP and
DD in published reports, but this relationship has not been
previously examined for asymptomatic vascular-laboratory-
detected progression. The current results suggest there
may be little relationship.
Although previous studies of PAD patients have sug-
gested higher event rates than were recorded in this study,
the entry criteria for stable disease and the well-known
beneficial effects of participation in a randomized trial may
Fig 2. Life-table survival curves for death from cardiova
tertiles of D-dimer levels.
Fig 3. Life-table survival curves for the primary compo
progression, vascular death, myocardial infarction, strok
C-reactive protein (CRP) levels.have selected/influenced the event rate in a negative direc-tion. Alternately, the end points included in the analysis
may not have been sensitive to CRP or DD levels. Had we
chosen clinical end points such as the onset of rest pain,
ischemic tissue loss, or evidence of plaque rupture, the
findings may have been different.
Our findings that DD levels were minimally associated
with the progression of symptomatic PAD are consistent
with those of the Edinburgh Artery Study.14 In that study
1500 men and women were followed for 5 years in an
attempt to detect the onset of PAD and determine whether
elevated levels of DD were related to the progression of
symptomatic PAD. These authors showed that DD levels
r disease and death from any cause for highest vs lowest
nd point (ankle-brachial index decrease, carotid duplex
putation) for highest vs lowest tertiles of D-dimer andsculasite e
e, amwere higher in patients who had worsening ischemia; how-
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Volume 43, Number 4 Musicant et al 777ever, they found no factors that were predictive of disease
progression by multivariate analysis.14
Despite the paucity of research showing an influence of
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CRP and DD. These findings were true for subjects with
and without PAD.
The obvious question that arises when studying the
effects of nonspecific markers of inflammation and throm-
bosis, such as DD and CRP, is the clinical relevance of these
associations. Our data suggest little role for use of these
markers as initial screening tests for the presence of PAD or
for the risk of progression of symptomatic PAD.
CONCLUSION
Baseline DD levels were significantly associated with
time to subsequent myocardial infarction in patients with
symptomatic PAD. Baseline CRP was not related to any
progression end point. Further research is needed to inves-
tigate the causative mechanisms involved, and larger pro-
spective studies are needed to confirm the validity of these
associations and determine the clinical utility of these mea-
sures.22
AUTHOR CONTRIBUTIONS
Conception and design: LMT, GLM, SEM
Analysis and interpretation: LMT, SEM, DP, RAS
Data collection: SEM, RAS, RU
Table III. Hazard ratios (with 95% confidence intervals) f








Age 1.01 1.01 1.00
(.99-1.03) (.99-1.03) (.96-1.05)
Rand group .93 .91 .80
(.66-1.31) (.66-1.26) (.39-1.64)
Gender .70 .69* .55
(.49-1.01) (.49-.98) (.25-1.22)
Diabetes 1.342 1.36 1.43
(.95-2.14) (.92-2.03) (.61-3.33)
Tobacco 1.21 1.23 .94
(.84-1.74) (.87-1.74) (.42-2.10)
Log-cholesterol§ 2.32 2.61* 14.77*
(.87-6.22) (1.00-6.76) (1.70-128.3) (
Hypertension .96 .94 .52
(.68-1.37) (.67-1.32) (.26-1.05)
Log-homocysteine§ 1.65* 1.68* 4.12*
(1.00-2.73) (1.04-2.74) (1.76-9.64)
Log-D-dimer 1.07 1.05 1.12
(.91-1.25) (.90-1.22) (.80-1.58)
Log-CRP .90 .94 1.17
(.75-1.08) (.79-1.11) (.81-1.68)
MI, Myocardial infarction; ABI, ankle-brachial index; CRP, C-reactive prot
Values were obtained by means of multivariate Cox proportional hazard
hypertension, log-cholesterol, and log-homocysteine.
*Values significant at P  .05.
†Composite end point includes vascular death, myocardial infarction, stroke
‡Variables were those determined at baseline.
§Hazard ratio estimates and confidence intervals correspond to an approxim
**There were too few amputation end points to analyze (P values were 1.00Writing the article: SEM, LMTCritical revision of the article: LMT, GLM, DP, RAS
Final approval of the article: LMT, SEM, DP, RAS




1. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology
of peripheral arterial disease: importance of identifying the population at
risk. Vasc Med 1997;2:221-6.
2. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective
blinded study of the relationship between plasma homocysteine and
progression of symptomatic peripheral arterial disease. J Vasc Surg
1999;29:8-21.
3. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic
atherosclerosis. JAMA 2002;285:2481-5.
4. Hackman DG, Anand SS. Emerging risk factors for atherosclerotic
vascular disease: a critical review of the evidence. JAMA 2003;290:
932-40.
5. Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Fibrin D-dimer, haemo-
static factors and peripheral arterial disease. ThrombHaemost 1995;74:
828-32.
6. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al.
Inflammatory markers and the risk of coronary heart disease in men and
women. N Engl J Med 2004;351:2599-610.
7. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH,
et al. C-reative protein levels and outcomes after statin therapy. N Engl








01 1.00 1.09 1.00 1.02
1.07) (.92-1.08) (.99-1.20) (.97-1.03) (1.00-1.05)
75 1.35 .85 .76 .84
2.01) (.38-4.85) (.22-3.28) (.47-1.25) (.54-1.30)
58 .26 .37 .96 .69
1.71) (.05-1.33) (.08-1.62) (.58-1.59) (.43-1.09)
20 6.34* 3.04 1.82* 1.36
4.23) (1.59-25.28) (.63-14.55) (1.04-3.18) (.80-2.32)
08 .84 .79 1.49 1.10
3.16) (.21-3.34) (.16-3.92) (.89-2.50) (.69-1.76)
44 31.66 89.72* .78 3.78*
12.1) (.87-1154) (1.89-4257.2) (.20-3.06) (1.10-12.96)
42 3.93 1.68 1.09 1.00
1.12) (.81-19.08) (.40-7.10) (.65-1.83) (.64-1.58)
52 .52 .07* 2.33* 1.04
8.30) (.08-3.29) (.01-.77) (1.17-4.61) (.54-2.01)
43 2.31* 1.61 .84 1.16
2.30) (1.12-4.76) (.76-3.44) (.67-1.04) (.94-1.43)
88 .63 .62 .85 .89
1.48) (.32-1.22) (.30-1.30) (.66-1.10) (.70-1.12)
lysis adjusted for age, gender, randomization group, diabetes, smoking,
utation, ABI progression, carotid progression.
0% increase on the original (untransformed) scale.



























ate 1J Med 2005;352:20-8.
JOURNAL OF VASCULAR SURGERY
April 2006780 Musicant et al8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Plasma concentration of C-reactive protein and risk of developing
peripheral vascular disease. Circulation 1998;97:425-8.
9. Garcia BA, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity
C-reactive protein in high-grade carotid stenosis: risk marker for unsta-
ble carotid plaque. J Vasc Surg 2003;38:1018-24.
10. Dósa E, Rugonfalvi-Kiss S, Prohászka Z, Szabó A, Karádi I, Selmeci L,
et al. Marked decrease in the levels of two inflammatory markers,
hs-C-reative protein and fibrinogen in patients with severe carotid
atherosclerosis after eversion carotid endarterectomy. Inflamm Res
2004;53:631-5.
11. Lowe GDO, Yarnell JW, Rumley A, Bainton D, Sweetnam PM.
C-reactive protein, fibrin D-dimer, and incident ischemic heart disease
in the Speedwell Study. Arterioscler Thromb Vasc Biol 2001;21:603-10.
12. McDermott MM, Green D, Greenland P, Liu K, Criqui MH, Chan C,
et al. Relation of levels of hemostatic factors and inflammatory markers
to the ankle brachial index. Am J Cardiol 2003;92:194-9.
13. van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C,
et al. Activation products of the haemostatic system in coronary, cere-
brovascular and peripheral vascular disease. ThrombHaemost 2001;85:
234-9.
14. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GD, Fowkes FG. Plasma
fibrinogen, haemostatic factors and prediction of peripheral arterial
disease in the Edinburgh Artery Study. Blood Coag Fibrinol 2000;11:
43-50.
15. McDermott MM, Greenland P, Guralnik JM, Ferrucci L, Green D, Liu
K, et al. Inflammatory markers, D-dimer, pro-thrombotic factors, and
end points and baseline CRP and DD levels. The data werephysical activity in patients with peripheral arterial disease. Vasc Med
2004;9:107-15.
16. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH,
Liu K, et al. D-dimer, inflammatory markers and lower extremity
functioning in patients with and without peripheral arterial disease.
Circulation 2003;107:3191-8.
17. Baur GM, Zupan TL, Holmgren-Gates K, Porter JM. Blood flow in the
common femoral artery. Am J Surg 1983;145:585-8.
18. Strandness DE Jr. Extracranial arterial disease. In: Strandness DE Jr,
editor. Duplex scanning in vascular disorders. 2nd edition. New York:
Raven Press; 1993. p. 113-58.
19. Yeager RA, Taylor LM Jr, Porter JM. The present status of infrainguinal
arterial reconstructive surgery for chronic lower extremity ischemia.
Curr Prob Surg 1991;28:125-39.
20. North American Symptomatic Carotid Endarterectomy (NASCET)
Steering Committee. North American Symptomatic Carotid Endarter-
ectomy Trial: methods, patient characteristics and progress. Stroke
1991;22:711-20.
21. Asymptomatic Carotid Atherosclerosis Study Group. Study design for
randomized prospective trial of carotid endarterectomy for asymptom-
atic atherosclerosis. Stroke 1989;20:844-9.
22. McDermott MM, Guralnik JM, Greenland P, Green D, Liu K, Ridker
PM, et al. Inflammatory and thrombotic blood markers and walking-
related disability inmen andwomenwith andwithout peripheral arterial
disease. J Am Geriatr Soc 2004;52:1888-94.Submitted Jun 21, 2005; accepted Dec 5, 2005.INVITED COMMENTARYStuart I. Myers, MD, Richmond, Va
This study is a prospective evaluation of the relationship
between C-reactive protein (CRP), and D-dimer (DD) and the
progression of peripheral arterial disease (PAD). The authors are
probing an important yet controversial clinical area. For the aver-
age reader, the presentation will be confusing and somewhat
bewildering, as this article has been written for those who under-
stand these types of trials and statistics. However, even the casual
reader will be able to understand the fundamental questions and
conclusions.
The authors studied 332 of 384 enrolled patients over a 7-year
period. The patients were originally part of the Homocysteine and
Progression of Atherosclerosis Study (HPAS). This trial started in
1991, and the first phase examined the relationship between the
homocysteine level and progression of PAD. The second phase of
the trial is a prospective, randomized, double-blind study examin-
ing the effects of folate vs placebo to prevent the progression of
PAD.
The current study represents a secondary set of objectives
derived from the second phase trial. The authors are presenting
data that examined the relationship between time to the variousexamined by life-table analysis and Cox proportional hazards anal-
ysis. The data showed that in subjects with symptomatic PAD,
death from a cardiovascular cause was slightly more likely in those
with elevated baseline DD and that DDwas significantly associated
with the occurrence of myocardial infarction. However, the study
did not find a relationship between progression of PAD and
baseline DD or CRP. The findings of this study appear straightfor-
ward and are very important, as several other studies have sug-
gested that DD andCRP as goodmarkers to predict progression of
PAD.
In summary, the study is extremely well designed and very well
described. The study is important for two reasons. First, the
authors have examined an important scientific and clinical question
and have provided the reader with data showing that DD and CRP
are not good markers of progression of PAD. These findings are
contrary to several previous studies and as such are somewhat
controversial. Second, this study is also important because it serves
as an excellent example of how to design a clinical trial that has far
reaching importance, yet examines very straightforward and simple
hypotheses.
